Protective Effect of 5-Alpha Reductase Inhibitors on Atherosclerotic Cardiovascular Disease in Populations With BPH: Evidence From UK Biobank Cohort and Chinese Single Center Database Studies

N/ACompletedNCT07196280

Chinese PLA General Hospital10,000 enrolled

Overview

To assess the impact of 5-alpha reductase inhibitors (5-ARIs) on the incidence of atherosclerotic cardiovascular disease (ASCVD) in patients with benign prostatic hyperplasia (BPH).

Study Type

OBSERVATIONAL

Enrollment

10,000

Conditions

Atherosclerotic Cardiovascular Disease (ASCVD)Benign Prostatic Hypertrophy (BPH)

Interventions

5-Alpha Reductase InhibitorsDRUG

Building on prior studies, drug exposure was defined as receiving 5-ARIs on at least two separate occasions, with an interval of no more than 180 days between prescriptions. Based on exposure status, the cohort was stratified into two groups.

Eligibility

Sex: MALEMin age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients diagnosed with BPH or users of 5-ARIs Exclusion Criteria: * individuals who had cancer prior to the start of follow-up and those with pre-existing ASCVD

Outcomes

Primary Outcomes

Atherosclerotic Cardiovascular Disease

While both CVD and ASCVD are composite disease categories, CVD encompasses a broader range of cardiovascular and cerebrovascular conditions. To ensure homogeneity in disease classification, we focused on ASCVD, which primarily refers to atherosclerosis-related cardiovascular and cerebrovascular diseases, including ischemic heart disease (IHD) and cerebrovascular disease (CeVD)

Time frame: Started taking 5α-reductase inhibitors until December 1, 2022

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.